Hutchison China MediTech Limited (Chi-Med) is the holding company of a pharmaceutical and healthcare group, which is engaged in the research, development, manufacture and sale of pharmaceuticals, health supplements and other consumer health and personal care products derived from traditional Chinese medicine (TCM) and botanical ingredients. The Company operates in three main areas: China healthcare, which comprises the development, manufacture, distribution and sale of TCM pharmaceuticals and health supplements; consumer products business, which relates to TCM-based consumer products sold through retail stores, and drug research and development, which relates mainly to pharmaceutical research and development. The Company is developing Sen as a TCM consumer brand in TCM medicines and treatments, food and beverage, and skin and body care products through its own network of retail stores.
11/05/12
Result of AGM10/04/12
2011 Annual Report and Notice of AGM20/03/12
Final Results22/02/12
Novel c-Met inhibitor Volitinib Enters the Clinic20/02/12
Notice of Results14/02/12
Holding(s) in Company02/02/12
Total Voting Rights05/01/12
Holding(s) in Company29/12/11
Blocklisting Six Monthly Return21/12/11
CANCER THERAPY COLLABORATION WITH ASTRAZENECA
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
